Latest Medtronic Plc News and Updates
What to Expect from St. Jude Medical’s Earnings in 2Q16
In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.
Farallon Capital adds a new position in Covidien
Ireland-based Covidien is a global healthcare leader that offers innovative medical technology solutions and patient care products to providers.
What Does Johnson & Johnson Predict for Its Medical Devices Segment?
Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.
Will Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18?
In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.
Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17
Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.
How Has Medtronic’s Stock Performed Recently?
Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump
Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.
Medtronic’s Revenue Is Estimated to Rise in Fiscal 2Q17
On November 22, 2016, Medtronic (MDT) will announce its fiscal 2Q17 earnings for the period that ended on October 31, 2016.
Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results
On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.
Tandem Diabetes Care’s International Expansion Strategy
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
Analysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.
How Tax Reform Affected Medtronic’s 3Q18 Performance
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
Diabetes Management Breakthrough: Medtronic’s MiniMed 670G
On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.
Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings
Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.
Fitbit’s Team Strategy: The Benefits of Acquisitions and Partnerships
In 2016, Fitbit (FIT) inked a deal with Pebble to harvest certain Pebble assets, now that the latter company has begun shutting down operations.
Boston Scientific Expands Its Endoscopy Business with EMcision Acquisition
On March 5, 2018, Boston Scientific (BSX) announced the acquisition of EMcision, which will expand the company’s endoscopy business.
Medtronic’s Key Growth Driver: MiniMed 670G Hybrid Closed Loop
Medtronic’s Diabetes Group performance in fiscal Q4 2018 was driven by a 25% growth for its MiniMed 670G hybrid closed-loop insulin pump.
What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?
Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.
ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.
Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results
Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.
Analysts’ Recent Recommendations and Target Price for ABT Stock
On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”
Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?
For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.
Tandem Diabetes Care’s Stock Performance This Month
On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.
Abbott Laboratories’ Stock Price Performance in July
Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.
Trade War Fears Triggered Medtronic’s Stock Decline on March 23
Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.
Innovative Products Driving Medtronic’s Growth
Medtronic expects its MITG segment to have an organic growth rate of 4% in fiscal 2019.
How Has Boston Scientific Stock Performed Recently?
Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.
How Johnson & Johnson’s Partnerships Enhance Customer Value
Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.
Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings
On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.
BSX Stock Regains Momentum after Its Recent Bearish Trend
On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.
Stryker’s Recent Stock Price Movement: Upside Potential?
Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.
A Look at Medtronic’s Recent Stock Performance
Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.
Must-know: Key export barriers for medical device manufacturers
Most large U.S. manufacturers have invested significant capital into emerging markets, including Medtronics, Johnson & Johnson, GE, and Stryker.
Boston Scientific Stock in the Week Ended September 14
Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.
IBM Is Paving the Way for Watson Health: Acquisitions and Deals
IBM’s partnership with Apple is especially appealing. Watson Health will bring cloud services and analytics to Apple’s HealthKit and ResearchKit.
Wall Street Maintains ‘Strong Buy’ Recommendation for Stryker
Analysts’ recommendations Stryker (SYK) has registered strong results over the last few quarters and has been expanding at a fast pace through organic and inorganic growth. The company has made a number of acquisitions and expanded its market presence across product lines and regions. Its most recent earnings results were reported on October 26, 2017. For details, read […]
How BD-Bard Acquisition Will Strengthen International Presence
C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.
Abbott’s Freestyle Libre Gets Reimbursement Approval in France
Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.
Understanding Zimmer Biomet’s Latest Dividend Announcement
On December 18, 2017, Zimmer Biomet Holdings (ZBH) announced a quarterly cash dividend of $0.24 per share for fiscal 4Q17.
Must-know: Is the Time Warner Cable–Comcast deal a “do?”
Arbs generally avoid utility deals—and for good reason. Typically, the companies have an aggressive expected timeline and these deals don’t close on time.
Abbott Laboratories’s Valuation before Its 2Q16 Results
After the release of its 1Q16 earnings results on April 20, 2016, Abbott Laboratories (ABT) was trading at a forward PE multiple in the range of 16.4x–19.3x.
Understanding JNJ’s Latest Stock Price Rise
On July 20, 2017, JNJ stock was trading at its 52-week high of $137.1, which was ~25.4% above its 52-week low of $109.3 on December 7, 2016.
Behind JNJ’s Recent Stock Price Performance: Is More Growth Coming?
Johnson & Johnson (JNJ) has seen a few disappointing quarterly performances, but on October 17, when JNJ announced its 3Q17 results, the stock gained 3.4%.
Brazil’s medical device industry: Health coverage outlook
The upward trends of the healthcare market show that Brazil is positive for the medical device industry, suggesting rapid increases in demand as more and more people can afford the devices and pay accordingly.
What Can We Expect for Stryker’s Earnings in 2Q16?
In 1Q16, Stryker exceeded analysts’ EPS (earnings per share) estimate of $1.20, as well as the revenue estimate of ~$2.5 billion.
Abbott Laboratories Posted Its Q1 Earnings, Stock Rose 4%
At 10:07 AM ET today, Abbott Laboratories (NYSE:ABT) stock rose by about 3.9%. The company reported its first-quarter financial results.
Abbott’s Q1 Earnings Report Might Boost Its Stock
Abbott Laboratories (NYSE:ABT) stock rose by about 1.0% in extended trading on Thursday. The stock rose 1.3% and closed at $86.04.
D.E. Shaw & Co.: Where Is David Shaw Bullish?
At the end of Q3 2019, D.E. Shaw & Co.’s total portfolio of publicly traded securities was worth around $81.2 billion.
Highlights of CalPERS holdings in 4Q14
CalPERS noted that it has recovered approximately $900 million to date from settlements related to investment losses sustained during the financial crisis.
Wellington Management: Analyzing Its Top Holdings
Wellington Management filed its 13F on Wednesday. Based on the filing, the market value of total publicly traded securities was around $443.45 billion.
Must-know market update: Is Puerto Rico losing its salsero vibe?
The charm of the island has been overshadowed with feelings of pessimism regarding the fiscally distressed state of the economy.
Amazon Partners with over 30 Companies: VI Initiative
On September 24, Amazon (AMZN) announced the Voice Interoperability Initiative. The announcement was one day before the Amazon hardware event.
These Developments Impacted Abbott Laboratories the Most in Fiscal 2017
Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.
Why Pfizer Stock Continues to Tank after Mylan Deal
Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.
What Is Medtronic Guiding for Its Business Segments in 2020?
In the fourth quarter, Medtronic’s spine business reported revenue of $691 million, a YoY fall of 1.1% on a reported basis.
Emerging Markets: Medtronic’s Key Revenue Driver in 2019
In the fourth quarter, Medtronic earned revenue of $4.28 billion in the US market, a YoY (year-over-year) rise of 2.3% on a reported and constant-currency basis.
Medtronic Guides for Robust Free Cash Flow Conversion for 2020
During its 2018 Investor Day presentation, Medtronic (MDT) set a target of 80% FCF (free cash flow) conversion.
How Did Medtronic’s Restorative Therapies Group Perform?
Medtronic’s (MDT) Spine Therapies generated revenues of $1.3 billion in the first half of fiscal 2019.
How Medtronic’s Minimally Invasive Therapies Group Has Performed
Medtronic’s MITG segment generated revenues of $4.1 billion in the first half of fiscal 2019 compared to $4.4 billion in the first half of fiscal 2018.
A Look at Medtronic’s Cardiac & Vascular Group’s Revenue Streams
Medtronic’s (MDT) Cardiac Rhythm & Heart Failure segment generated revenues of $1.47 billion in the second quarter of fiscal 2019.
A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019
Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018.
How Wall Street Analysts View Medtronic in December
Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”
How IBM Is Investing in AI Solutions
AI is the buzzword these days, and the market has huge growth potential.
Sanofi: Analysts’ Recommendations on October 30
As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”
Why Morningstar Is Overweight on Healthcare
As the third graph shows, the Morningstar US Wide Moat Focus Index has over a 30% weight in healthcare, while the S&P 500 Index has only a 15% weight in the sector.
Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings
Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.
Thermo Fisher’s Third-Quarter Revenue Estimates
The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.
How Intuitive’s Bottom Line Is Expected to Look in Q3 2018
Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% to $265.76 million in the third quarter of 2018.
ABT Stock Registered a 52-Week High in October
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.
How GlaxoSmithKline’s Pharmaceutical Business Performed
GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.
EW Stock Returned More than the S&P 500’s Gain in 2018
As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.
High Valuation Multiples: Is EW Stock an Expensive Bet?
On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.
What ViewRay’s Valuation Trend Indicates
In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.
What’s the Upside Potential for Agilent Technologies Stock?
In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.
ABT Returns Almost Double the S&P 500’s Year-to-Date Gain
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).
Abbott Laboratories Stock Trades at Its 52-Week High in September
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.
Thermo Fisher to Offer Complete Cannabis Testing Solutions
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
How Thermo Fisher Scientific’s Valuation Looks in September
Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.
Analysts Still Bullish on Teleflex Stock
Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018.
What Analysts Expect for Abiomed
Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018.
Do Abiomed’s Valuations Look Attractive?
Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.
How Analysts View Becton Dickinson in August 2018
On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65.
Here’s What Varian Medical Systems’ Valuation Trend Indicates
Of the nine analysts covering Varian Medical Systems (VAR) stock, three have given it a “strong buy,” three have given it a “hold,” and three have given it a “sell.”
GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products.
What Analysts Expect from Haemonetics in Q1 2019
Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.
How Baxter International Fared in the Second Quarter
Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.
Assessing BSX’s Recently Acquired Cryterion Cryoablation Platform
On July 5, Boston Scientific announced its acquisition of Cryterion Medical, which will add Cryterion’s cryoablation platform to BSX’s atrial fibrillation treatment portfolio.
Commercial Launch of NexSys PCS May Boost Haemonetics’s Revenues
Haemonetics is also involved in plasma donor center experience programs that involve the use of NexSys PCS device and YES technology.
How the Healthcare Sector’s Dividend Yield Stacks Up
The healthcare industry has an average dividend yield of 1.9%.
MitraClip Drives Growth, Gets Reimbursement Approval in Japan
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.
The Hospital Business Remains 1of HAE’s Key Growth Drivers
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%.
Medtronic’s New Partnership to Deliver Value-Based Healthcare
On February 28, 2018, Medtronic (MDT) announced that it has entered into a partnership with LVHN (Lehigh Valley Health Network), an eight-hospital network.
Medtronic Launches Its Resolute Onyx 2.0 mm DES
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved the launch of its Resolute Onyx 2.0 mm DES.
FDA Approves Arm Indication for Medtronic’s Guardian Sensor 3
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3.
Medtronic Strengthens Diabetes Business with MiniMed Infusion Set
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set.
What’s Abbott Laboratories’ Current Valuation?
As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x.
ABT Gets FDA Approval for World’s Smallest Mechanical Heart Valve
Abbott announced that it received FDA approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants.
BSX Stock Rises More Than 2% Following EMcision Acquisition
Boston Scientific’s recent stock performance On March 6, 2018, Boston Scientific (BSX) stock closed at $27.41, higher than its 50-day moving average of $27.15 and lower than its 200-day moving average of $27.52. As of March 7, 2018, Boston Scientific’s 52-week high was $29.93 on October 23, 2017, and its 52-week low was $24.02 on March 22, 2017. Factors […]